Ranbaxy to Bring in Daiichi Sankyo as Majority Partner; Strategic Combination Creates Innovator and Generic Pharma Powerhouse



    TOKYO, Japan and NEW DELHI, India, June 11 /CNW/ - Daiichi Sankyo
Company, Limited (TSE: 4568.JP) ("Daiichi Sankyo"), one of the largest
pharmaceutical companies in Japan, and Ranbaxy Laboratories Limited
(NSE/BSE: Ranbaxy/500359) ("Ranbaxy"), among the top 10 generic companies in
the world and India's largest pharmaceutical company, announced on June 11
that a binding Share Purchase and Share Subscription Agreement (the "SPSSA")
was entered into between Daiichi Sankyo, Ranbaxy and the Singh family, the
largest and controlling shareholders of Ranbaxy (the "Sellers"). Pursuant to
the Agreement, Daiichi Sankyo will acquire the entire shareholding of the
Sellers in Ranbaxy and further seek to acquire the majority of the voting
capital of Ranbaxy at a price of Rs737 per share with the total transaction
value expected to be between US$3.4 to US$4.6 billion (currency exchange rate:
US$1=Rs43). On the post-closing basis, the transaction would value Ranbaxy at
US$8.5 billion.

    For more details, please check full text of the press release from
Daiichi Sankyo website: http://www.daiichisankyo.com/




For further information:

For further information: Motomi Takahashi (for Daiichi Sankyo), Dentsu
Public Relations Inc., Phone: +81-3-5565-8434, E-mail:
m-takahashi@dentsu-pr.co.jp; Ramesh L. Adige (for Ranbaxy), Executive Director
- Corporate Affairs and Global Corporate Communications, Ranbaxy Laboratories
Limited, Phone: +91-124-4135000, E-mail: ramesh.adige@ranbaxy.com

Organization Profile

Daiichi Sankyo Company, Limited

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890